Inclusion Criteria:

- Histologically proven adenocarcinoma of the pancreas

- Metastatic or locally advanced, non resectable disease(Non resectable disease will be
determined by the investigators with clinical data)

- Uni-dimensionally measurable disease as defined by RECIST (primary or secondary
tumors>2cm using conventional CT scan or ≥1cm with spiral CT scan)

- No previous chemo or radiotherapy, but postoperative radiotherapy as a adjuvant
therapy for non-target lesion is permitted

- Karnofsky Performance Status (KPS) ≥60

- No known Central Nervous System metastases

- No sensory neuropathy at inclusion

- Biological and hematological evaluation < 2 weeks prior to treatment administration:

- Neutrophils ≥ 1500/ mm3

- Platelets ≥ 100,000/mm3

- Alkaline phosphatases< 5X ULN(upper Limits of Normal) and Bilirubin < 1.5X ULN

- SGOT,SGPT <2.5 X ULN if no liver metastasis

- SGOT,SGPT <5 X ULN if liver metastasis

- Creatinine < 1.5 X ULN

- Baseline imaging (CT scan or Magnetic Resonance Imaging) <3 weeks before treatment
administration

- Men and women who are fertile must use a medically acceptable contraceptive
throughout the treatment period and for 3 months following cessation of treatment
with oxaliplatin. Subjects must be made aware, before entering this trial of the risk
of becoming pregnant or in fathering children

Exclusion Criteria:

- Corticotherapy except for anti-emetic purpose

- Pregnant or breast feeding women (Documentation of a negative pregnancy test must be
available for premenopausal women with intact reproductive organs)

- Uncontrolled congestive heart failure or angina pectoris, or hypertension or
arrhythmia

- Uncontrolled or persistent hypercalcemia

- History of significant neurologic or psychiatric disorders

- Vater ampulomas and biliary tract adenocarcinomas

- Other -non cured- malignancies

The above information is not intended to contain all considerations relevant to a
patient's potential participation in a clinical trial.